Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir in treatment-naive HIV-1-infected patients
Stellbrink, Hans-Jürgen × Arastéh, Keikawus Schürmann, Dirk Stephan, Christoph Dierynck, Inge Smyej, Ilham Hoetelmans, Richard M W Truyers, Carla Meyvisch, Paul Jacquemyn, Bert Mariën, Kris Simmen, Kenneth Verloes, Rene #
Lippincott Williams & Wilkins
Journal of Acquired Immune Deficiency Syndromes vol:65 issue:3 pages:283-289
TMC310911 is a novel human immunodeficiency virus type-1 (HIV-1) protease inhibitor with broad in vitro antiviral activity. In this phase 2a, open-label, randomized study, the antiviral activity, pharmacokinetics, and safety and tolerability of ritonavir-boosted TMC310911 was assessed.